Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry.

Diagnosis Lung cancer Lung neoplasms

Journal

Archivos de bronconeumologia
ISSN: 1579-2129
Titre abrégé: Arch Bronconeumol
Pays: Spain
ID NLM: 0354720

Informations de publication

Date de publication:
15 Jul 2024
Historique:
received: 28 05 2024
revised: 28 06 2024
accepted: 01 07 2024
medline: 28 7 2024
pubmed: 28 7 2024
entrez: 27 7 2024
Statut: aheadofprint

Résumé

Early detection is crucial to improve lung cancer survival rates. Delays in diagnosis might negatively impact the prognosis of the disease. This study aims to analyze the diagnostic delay in lung cancer patients and describe if there is an association between delay and survival. The data source used was the Thoracic Tumor Registry of the Spanish Lung Cancer Group. This analysis was restricted to lung cancer cases with information on the first date of consultation by symptoms and date of diagnosis. The delay was calculated as the number of days between the two dates. A descriptive analysis was performed, and ordinal logistic regressions were fitted with delay as the dependent variable. Kaplan-Meier survival analysis and Cox regression were performed. 22,755 lung cancer cases were included. Never smokers were 1.16 (95%CI: 1.06-1.27) times more likely to register longer delay than smokers. Stage 0-I-II cases had a 3.09 (95%CI: 2.88-3.32) higher risk of longer delay compared to III-IV stages. Overall, 5-year survival rate after diagnosis was 23.64% (95%CI: 22.88-24.41). In those categorized as having the shortest delay 5-year survival was 17.67% (95%CI: 16.31-19.07) and in the extreme delay it was 32.98% (95%CI: 31.28-34.69) (p<0.001). Adjusted mortality risk was higher in those with the shortest delay (HR 1.36, CI95%: 1.30-1.43) in comparison with the extreme delay. Diagnostic delay is short among Spanish lung cancer patients, indicating a relatively quick diagnostic process. Extreme delays appear to be associated with higher survival rates, possibly attributed to slow-growing tumors, earlier stage at diagnosis or basically the natural history of this disease.

Sections du résumé

BACKGROUND BACKGROUND
Early detection is crucial to improve lung cancer survival rates. Delays in diagnosis might negatively impact the prognosis of the disease. This study aims to analyze the diagnostic delay in lung cancer patients and describe if there is an association between delay and survival.
METHODS METHODS
The data source used was the Thoracic Tumor Registry of the Spanish Lung Cancer Group. This analysis was restricted to lung cancer cases with information on the first date of consultation by symptoms and date of diagnosis. The delay was calculated as the number of days between the two dates. A descriptive analysis was performed, and ordinal logistic regressions were fitted with delay as the dependent variable. Kaplan-Meier survival analysis and Cox regression were performed.
RESULTS RESULTS
22,755 lung cancer cases were included. Never smokers were 1.16 (95%CI: 1.06-1.27) times more likely to register longer delay than smokers. Stage 0-I-II cases had a 3.09 (95%CI: 2.88-3.32) higher risk of longer delay compared to III-IV stages. Overall, 5-year survival rate after diagnosis was 23.64% (95%CI: 22.88-24.41). In those categorized as having the shortest delay 5-year survival was 17.67% (95%CI: 16.31-19.07) and in the extreme delay it was 32.98% (95%CI: 31.28-34.69) (p<0.001). Adjusted mortality risk was higher in those with the shortest delay (HR 1.36, CI95%: 1.30-1.43) in comparison with the extreme delay.
CONCLUSIONS CONCLUSIONS
Diagnostic delay is short among Spanish lung cancer patients, indicating a relatively quick diagnostic process. Extreme delays appear to be associated with higher survival rates, possibly attributed to slow-growing tumors, earlier stage at diagnosis or basically the natural history of this disease.

Identifiants

pubmed: 39068056
pii: S0300-2896(24)00268-0
doi: 10.1016/j.arbres.2024.07.006
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Cristina Candal-Pedreira (C)

Area of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Spanish Lung Cancer Group, Spain.

Alberto Ruano-Ravina (A)

Area of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain; Spanish Lung Cancer Group, Spain. Electronic address: alberto.ruano@usc.es.

Virginia Calvo de Juan (V)

Spanish Lung Cancer Group, Spain; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.

Manuel Cobo (M)

Spanish Lung Cancer Group, Spain; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain.

Alexandra Cantero (A)

Spanish Lung Cancer Group, Spain; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain.

Delvys Rodríguez-Abreu (D)

Spanish Lung Cancer Group, Spain; Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain.

Anna Estival (A)

Spanish Lung Cancer Group, Spain; Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain.

Enric Carcereny (E)

Spanish Lung Cancer Group, Spain; Institut Català D'Oncologia Badalona - Hospital Germans Trias i Pujol, B-ARGO, IGTP, Badalona, Spain.

Ainhoa Hernandez (A)

Spanish Lung Cancer Group, Spain; Institut Català D'Oncologia Badalona - Hospital Germans Trias i Pujol, B-ARGO, IGTP, Badalona, Spain.

Rafael López Castro (R)

Spanish Lung Cancer Group, Spain; Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

Andrea Medina (A)

Spanish Lung Cancer Group, Spain; Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

Rosario García Campelo (R)

Spanish Lung Cancer Group, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.

Manuel Fernández Bruno (M)

Spanish Lung Cancer Group, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.

Reyes Barnabé (R)

Spanish Lung Cancer Group, Spain; Hospital Universitario Virgen del Rocio, Sevilla, Spain.

Joaquim Bosch-Barrera (J)

Spanish Lung Cancer Group, Spain; Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta and Precision Oncology Group (OncoGIR-Pro), Institut d'Investigacions Biomèdiques de Girona (IDIBGI), Girona, Spain.

Bartomeu Massutí (B)

Spanish Lung Cancer Group, Spain; Hospital General Universitario Dr. Balmis de Alicante, Alicante, Spain.

Manuel Dómine (M)

Spanish Lung Cancer Group, Spain; Hospital Universitario Fundación Jiménez Díaz. IIS-FJD, Madrid, Spain.

Carlos Camps (C)

Spanish Lung Cancer Group, Spain; Hospital General Universitario de Valencia, Valencia, Spain.

Ana Laura Ortega (AL)

Spanish Lung Cancer Group, Spain; Hospital Universitario de Jaén, Jaén, Spain.

Mariano Provencio (M)

Spanish Lung Cancer Group, Spain.

Classifications MeSH